Form 8-K

8-K — Eloxx Pharmaceuticals, Inc.

Accession: 0001193125-26-345032

Filed: 2026-08-11

Period: 2026-08-11

CIK: 0001035354

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d167833d8k.htm (Primary)

EX-99.1 (d167833dex991.htm)

GRAPHIC (g167833g0811235810481.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d167833d8k.htm · Sequence: 1

8-K

NASDAQ false 0001035354 0001035354 2026-08-11 2026-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2026

Eloxx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-31326

84-1368850

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

P.O. Box 274

10 Court Street, Arlington, MA 02476

(Address of principal executive offices, including zip code)

(781) 577-5300

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.01 par value per share

ELOX

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On August 11, 2026, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026 and providing a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Exhibit Description

99.1

Press release of Eloxx Pharmaceuticals, Inc.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 11, 2026

ELOXX PHARMACEUTICALS, INC.

By:

/s/ Sumit Aggarwal

Name:

Sumit Aggarwal

Title:

President and Chief Executive Officer

EX-99.1

Filename: d167833dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

•

Completed underwritten public offering with gross proceeds of $66.0 million and uplisting

to the Nasdaq Capital Market, significantly strengthening the Company’s balance sheet

•

Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third

quarter of 2026

•

European Commission granted orphan designation for exaluren in ADPKD

•

Cash and cash equivalents of $62.0 million as of June 30, 2026, expected

to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)

ARLINGTON, Mass., August 11, 2026 — Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company

developing exaluren for the treatment of rare kidney diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.

“The second quarter was transformational for Eloxx. Our public offering, with gross proceeds of $66.0 million, together with our uplisting to the

Nasdaq Capital Market, has meaningfully strengthened our balance sheet and provides the resources to advance exaluren across our rare kidney disease programs,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. “With

approximately $62.0 million in cash, no outstanding debt, and a clear clinical development plan, we believe we are well positioned to advance our Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome in the third quarter of

2026 and initiate a Phase 2 clinical trial in nonsense mutation ADPKD in 2027.”

Financing and Uplisting to Nasdaq

•

$66.0 million public offering. The Company completed an underwritten public offering

of 2,975,000 shares of common stock at a public offering price of $11.00 per share, together with pre-funded warrants to purchase up to 3,025,000 shares of common stock, for gross proceeds of approximately

$66.0 million and net proceeds of approximately $58.3 million, after deducting underwriting discounts and commissions and offering expenses.

•

Uplisting to Nasdaq. In June 2026, the Company completed its uplisting to the Nasdaq Capital Market,

where its common stock began trading under the symbol “ELOX.”

Recent Business Highlights

•

Exaluren in nonsense mutation Alport syndrome (NMAS). The Company received clearance under its

Investigational New Drug application from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2b clinical trial of exaluren in patients with NMAS and plans to initiate the trial in the third quarter of 2026. The Company anticipates

topline data from the initial 16-week placebo-controlled portion of the study by mid-2027, with the final readout by the end of 2027. Exaluren has received orphan drug

designation from the FDA and European Commission for the treatment of Alport syndrome.

•

Exaluren in ADPKD. In July 2026, the European Commission granted orphan medicinal product designation in

the European Union for exaluren for the treatment of ADPKD. The Company plans to initiate a Phase 2 clinical trial of exaluren in nonsense mutation ADPKD in 2027, with topline data anticipated by mid-2028.

•

Strengthened Board of Directors. In May 2026, the Company appointed Stephen W. Webster and Nina Kjellson

to its board of directors. Mr. Webster served as Chief Financial Officer of Spark Therapeutics, Inc. from 2014 until its acquisition by Roche in 2019, has previously held chief financial officer roles at Optimer Pharmaceuticals and Adolor

Corporation, and currently serves as a director of Cullinan Therapeutics, Inc. and NextCure, Inc. Ms. Kjellson has been a General Partner at Canaan Partners since 2015 and previously served as a General Partner at InterWest Partners, bringing

more than two decades of biotechnology investment and board experience.

•

ZKN-013. Almirall, S.A., is developing ZKN-013 for the treatment of rare dermatological diseases associated with nonsense mutations, including recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. The Company remains eligible

to receive development and sales milestones of up to approximately $470.0 million, as well as tiered royalties on any future global sales.

Second Quarter 2026 Financial Results

In May 2026,

the Company effected a one-for-eleven reverse stock split of its common stock and reduced its authorized shares of common stock from 500,000,000 to 100,000,000. All

share and per-share amounts in this press release reflect the reverse stock split.

Net loss for the

three months ended June 30, 2026 was $4.5 million, or $(0.39) per share, which included $0.1 million in stock-based compensation, compared to a net loss of $1.9 million, or $(5.45) per share, for the same period in 2025. For the

six months ended June 30, 2026, net loss was $8.3 million, compared to $3.6 million for the same period in 2025.

Research and

development (R&D) expenses were $2.8 million for the three months ended June 30, 2026, compared to $0.9 million for the same period in 2025. The increase was primarily related to increased clinical trial expenses in support of

the Company’s exaluren program, as well as increases in personnel costs and preclinical research and development activities.

General and

administrative (G&A) expenses were $1.6 million for the three months ended June 30, 2026, compared to $0.7 million for the same period in 2025. The increase was primarily related to higher professional and consulting fees,

including legal, audit and tax fees, and increased personnel costs.

Cash position. As of June 30, 2026, the Company had cash and cash

equivalents of $62.0 million, which includes approximately $58.3 million in net proceeds from the June 2026 public offering. The Company believes its cash and cash equivalents will be sufficient to fund its operations into mid-2028.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to

modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx’s lead product candidate, exaluren, is being developed for the treatment of rare

kidney diseases, including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A.,

which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.

For more information, please visit

www.eloxxpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than

statements of present and historical facts contained in this press release, including without limitation statements regarding the sufficiency of the Company’s cash and cash equivalents to fund its operations; the expected timing of the

initiation of, and results from, clinical trials of the Company’s product candidates, including the Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome and a planned Phase 2 clinical trial in ADPKD; the potential benefits

of orphan drug designation; the Company’s ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market; the Company’s collaboration with Almirall and the potential to receive milestone and royalty

payments; and the potential of the Company’s product candidates to treat nonsense mutations, are forward-looking statements. Forward-looking statements can be identified by words such as “aim,” “may,”

“will,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “potential,”

“seeks,” or “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management’s current plans,

estimates, assumptions and projections, and are subject to known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied due to various important factors, including, but not limited

to, the Company’s need for and ability to obtain additional capital; the uncertainty and expense of clinical development; the fact that results from preclinical studies and early clinical trials are not necessarily predictive of future

results; and other important factors discussed under the caption “Risk Factors” and elsewhere in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026

and its other filings with the SEC, accessible on the SEC’s website at www.sec.gov and on the “Financials & Filings” page of the Company’s website. All forward-looking statements speak only as of the date of this

press release and, except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements contained herein.

Contact

Investor Relations

Eloxx Pharmaceuticals, Inc.

ir@eloxxpharma.com

(781) 577-5300

ELOXX PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Operating expenses:

Research and development

2,840

898

4,500

1,408

General and administrative

1,610

684

3,746

1,396

Total operating expenses

4,450

1,582

8,246

2,804

Loss from operations

(4,450

)

(1,582

)

(8,246

)

(2,804

)

Other expense, net

309

796

Net loss

(4,502

)

(1,891

)

(8,256

)

(3,600

)

Net loss per share, basic and diluted

(0.66

)

(5.45

)

(1.48

)

(10.39

)

Weighted average number of shares of common stock and

pre-funded warrants used in computing net loss per share, basic and diluted

6,789,165

347,000

5,592,596

346,482

ELOXX PHARMACEUTICALS, INC.

Consolidated Balance Sheet Data

(in thousands, except share and per share amounts)

June 30,

2026

(unaudited)

December 31,

2025

Cash and cash equivalents

61,960

4,785

Total assets

63,388

5,270

Total current liabilities

16,968

17,177

Total stockholders’ equity (deficit)

46,420

(11,907

)

GRAPHIC

Filename: g167833g0811235810481.jpg · Sequence: 6

Binary file (4869 bytes)

Download g167833g0811235810481.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information

Aug. 11, 2026

Cover [Abstract]

Security Exchange Name

NASDAQ

Amendment Flag

false

Entity Central Index Key

0001035354

Document Type

8-K

Document Period End Date

Aug. 11, 2026

Entity Registrant Name

Eloxx Pharmaceuticals, Inc.

Entity Incorporation State Country Code

Entity File Number

001-31326

Entity Tax Identification Number

84-1368850

Entity Address, Address Line One

P.O. Box 274

Entity Address, Address Line Two

10 Court Street

Entity Address, City or Town

Arlington

Entity Address, State or Province

Entity Address, Postal Zip Code

02476

City Area Code

(781)

Local Phone Number

577-5300

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, $0.01 par value per share

Trading Symbol

ELOX

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration